Terumo Medical Corporation has announced today the introduction of its Azur vascular plug. The addition to Terumo’s embolisation portfolio is indicated for use to reduce or block the rate of blood flow in arteries of the peripheral vasculature.
“The Azur vascular plug represents a balance of properties—stability, accuracy, and reliable occlusion. This technology has unique advantages that truly make it a market first in embolotherapy, in line with Terumo’s ongoing efforts to deliver improved clinical outcomes and economic benefits,” said Chris Pearson, executive vice president, commercial operations, Terumo Interventional Systems.
A Terumo press release details that the Azur vascular plug comes in sizes to treat arterial anatomy ranging from 2.5–8mm, with a short deployment length for increased precision.
Features include a conformable nitinol braid and an expanded polytetrafluoroethylene (ePTFE) and polyethylene terephthalate (PET) inner composite membrane to facilitate mechanical occlusion. Another key element in the plug’s design is its “advanced, predictable” detachment mechanism, the statement reads, which allows for “immediate and reliable deployment with the push of a button”.
The launch of the Azur vascular plug is complemented by the introduction of the PG Pro peripheral microcatheter, which is indicated for the peripheral vasculature for the infusion of diagnostic and therapeutic agents.
The PG Pro microcatheter is designed specifically to deliver all three sizes of the Azur vascular plug. It comes in radial lengths up to 165cm and a 1,200 PSI rating for clearer fluoroscopic imaging. Both are currently only available in the USA.
“Together, these next-generation technologies allow physicians to treat larger, more difficult vessels through smaller delivery options. It is yet another way Terumo is providing the opportunity for operators to take advantage of the benefits of radial access for increasingly complex procedures, while enhancing therapeutic options in the peripheral vasculature with a microvascular plug. It is a welcome addition to our innovative, best-in-class portfolio,” added Michael Martinelli, chief medical officer, Terumo Medical Corporation.
